Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
Jul 15, 2020
Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients